Home/Pipeline/REC-3565

REC-3565

B-cell Malignancies

Phase 1Active

Key Facts

Indication

B-cell Malignancies

Phase

Phase 1

Status

Active

Company

Recursion Pharmaceuticals

About Recursion Pharmaceuticals

Recursion Pharmaceuticals aims to decode biology and radically improve lives by applying artificial intelligence and automation to drug discovery. Its core asset is the Recursion OS, a comprehensive platform that generates and analyzes petabytes of proprietary biological data to fuel an internal pipeline of potential first-in-class and best-in-class therapies. The company has advanced several programs into clinical trials, secured strategic partnerships with industry leaders, and is building one of the most powerful supercomputers in biopharma to scale its operations.

View full company profile

Therapeutic Areas

Oncology Rare Disease

Other B-cell Malignancies Drugs

Drug	Company	Phase	Status
Pirtobrutinib	Eli Lilly	Phase 3	Active
Mezagitamab	Kyowa Kirin	Phase 1/2	Active
Velexbru (tirabrutinib)	Ono Pharmaceutical	Phase 3	Active
KT-413	Kymera Therapeutics	Phase 1	Active
TG-1701	TG Therapeutics	Phase 1	Early-stage (based on general knowledge)
TG-1801	TG Therapeutics	Phase 1	Early-stage (based on general knowledge)
HMPL-760	HUTCHMED	Phase 1	Active
UCART20x22	Cellectis	Phase 1/2	Active (in collaboration with Servier)
FT819	Fate Therapeutics	Phase 1	Active
Prulacabtagene leucel (prula-cel, ADI-001)	Adicet Bio	Phase 1	Previously Studied